SecBot SecBot
S-1 ·Filed Nov 18, 2026

SBFM

Sunshine Biopharma Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3d 15h ago SEC0001683168-26-008932
IPO registration
Actionable Insight ▼ Bearish

Monitor whether Series B warrant holders exercise for cash given the stock trades below the current $2.7674 exercise price. The assumed $1.00 adjusted exercise price suggests further price adjustments are likely. Any exercise would be highly dilutive given the $2M market cap. Watch for Nasdaq compliance updates and potential delisting if the stock cannot maintain $1.00 bid price.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.35
T+0 close · Nov 18, 2026 · via day close
Latest settled
−5.11%
T+1 · $2.23
Vs SPY
−1.47%
α at T+1
Next horizon
T+5
in 5d
  1. T+0 · Nov 19 $2.35entry
  2. T+1 · 2d ago −5.11%α −1.47% · $2.23
  3. T+5 · in 5d Pending
  4. T+20 · in 26d Pending
  5. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sunshine Biopharma filed an S-1 registration statement to register 31,087,198 shares of common stock issuable upon exercise of outstanding Series B Warrants, with an assumed adjusted exercise price of $1.00 per share. The filing enables cash-only exercise of the warrants, potentially raising up to $31 million for general corporate purposes, but there is no assurance any warrants will be exercised. The company faces Nasdaq delisting risk due to bid price non-compliance and has a market cap of only $2 million, making this a highly dilutive and uncertain capital event.

Key Facts

  • S-1 registers 31,087,198 shares issuable upon exercise of 11,233,359 Series B Warrants at an assumed adjusted exercise price of $1.00 per share
  • Current exercise price is $2.7674, subject to further adjustment; last sale price on Nov 17, 2026 was $2.54 per share
  • If all warrants are exercised for cash, gross proceeds would be approximately $31 million; no minimum exercise amount
  • Company has a $2 million market cap and has completed four reverse stock splits since April 2024 (1-for-100, 1-for-20, 1-for-10, 1-for-20)
  • Nasdaq bid price non-compliance risk: stock traded below $1.00 prior to Oct 26, 2026 reverse split; subject to immediate delisting notice until October 2027
  • Approximately 12,526,050 total warrants outstanding as of filing date, subject to adjustment
  • 10 offering/registration filings in last 24 months; short interest of 176K shares (~23.2% of estimated shares outstanding)

Financial Impact

Up to $31 million gross proceeds if all Series B Warrants exercised for cash; no assurance of any exercise. Pro forma shares outstanding would increase from 4.3M to potentially 14.5M+ based on prior S-1, representing massive dilution.

dilutioncashshare count

Risk Factors

  • Nasdaq delisting risk: stock has repeatedly fallen below $1.00 bid price, requiring multiple reverse splits; subject to immediate delisting notice until October 2027
  • Extreme dilution: 31M shares registered vs. current market cap of $2M; pro forma shares could increase several-fold
  • No minimum offering amount: the S-1 has no assurance any warrants will be exercised, creating uncertainty about actual proceeds
  • Cash burn and going concern risk: company has only $13.7M in cash as of June 30, 2026 (from prior S-1) and needs additional capital
  • Proposed Nasdaq $5M market value of listed securities rule (currently stayed) would also pose delisting risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
S-1 Filing (Primary)0001683168-26-008932
Document: sunshine_ex0501.htm0001683168-26-008932
Document: sunshine_ex107.htm0001683168-26-008932
Document: sunshine_ex0312.htm0001683168-26-008932
Document: sunshine_ex2302.htm0001683168-26-008932
Document: sunshine_ex2301.htm0001683168-26-008932
Document: 0001683168-26-008932-index-headers.html0001683168-26-008932
Document: 0001683168-26-008932-index.html0001683168-26-008932
Document: 0001683168-26-008932.txt0001683168-26-008932

Track record

15 reports on SBFM

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +69.19% at T+20 after the Oct 8, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 18, 20263d ago S-1 Bearish 6/10 Viewing Entry $2.35 Now $2.23 +5.11% settles Nov 27
  2. Nov 13, 20268d ago DEFA14A Bearish 5/10 Entry $2.60 Now $2.23 +14.23% settles Nov 23
  3. Nov 12, 20269d ago DEF 14A Bearish 5/10 Entry $2.70 to $2.23 Now $2.23 +17.41% ▲ +17.41% +8.85% vs SPY
  4. Nov 10, 202611d ago SC 13G/A Neutral 2/10 Entry $2.75 to $2.41 Now $2.23 −18.91% ▼ −12.36% −8.47% vs SPY
  5. Oct 14, 20265w ago SC 13G Neutral 3/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
  6. Oct 13, 20265w ago SC 13G Neutral 4/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
  7. Oct 9, 20266w ago 8-K Bearish 6/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
  8. Oct 9, 20266w ago 424B4 Bearish 7/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
  9. Oct 8, 20266w ago EFFECT Bearish 6/10 Entry $8.60 to $4.60 Now $2.23 +74.07% ▲ +46.51% +46.24% vs SPY
  10. Oct 5, 20266w ago SC 13G/A Bearish 5/10 Entry $0.3979 to $0.2363 Now $2.23 −460.44% ▲ +40.61% +40.47% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Mon (25h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 18, 2026